Skip to main content
. Author manuscript; available in PMC: 2019 Jul 7.
Published in final edited form as: J Theor Biol. 2018 Apr 1;448:38–52. doi: 10.1016/j.jtbi.2018.03.035

Table 1.

Sample 21-day course drug combination regimens for treating patients with advanced (Stage IIIB/IV) non-small cell lung cancer (NSCLC).

Cisplatin Gemcitabine Reference
75 mg/m2 (day 1) 1250 mg/m2 (days 1 and 8) (Lee et al., 2004; Network, 2013; Scagliotti et al., 2008; Vergnenegre et al., 2009)
80 mg/m2 (day 1) 1250 mg/m2 (days 1 and 8) (Brodowicz et al., 2006; Perol et al., 2012)
100 mg/m2 (day 1) 1250 mg/m2 (days 1 and 8) (Cardenal et al., 1999)
75 mg/m2 (day 8) 1250 mg/m2 (days 1 and 8) (Akcali et al., 2008)